Intra-Cellular Therapies (ITCI) Tops Q4 EPS by 9c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. EBAY
6. TENB
7. BIIB
8. CMG
9. KLAC
10. ETSY

Go back to Intra-Cellular Therapies (ITCI) Tops Q4 EPS by 9c, Revenues Beat

Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2020 Financial Results And Provides Corporate Update

February 25, 2021 7:30 AM EST

Successfully launched CAPLYTA® (lumateperone) in late March 2020 and demonstrated strong commercial execution in the midst of COVID-19.

CAPLYTA achieved net product revenues of $12.4 million and $22.5 million for fourth quarter and full year 2020, respectively.

Fourth quarter CAPLYTA total prescriptions (TRx) increased 77% versus the previous quarter.

Pursuing CAPLYTA label expansion including bipolar depression and major depressive disorder:

Submitted CAPLYTA supplemental new drug applications (sNDAs) to the FDA... More